CD70 signaling enhances NK-cell antilymphoma responses. CD70 is triggered by CD27 expressed on lymphoma cells (1), resulting in CD70-transduced phosphatidylinositol 3-kinase (PI3K)/Akt pathway, resulting NK-cell activation (2). This interaction results in NK cell activation and multiple functional effects (3), which contribute to the protection of the host against lymphoma (4).